VH gene segments and CDR3–deduced amino acid sequences of HCV-associated NHLs and homology to protein sequence databases
| Patient no. . | IgH CDR3 deduced amino acid sequences . | Length of CDR3 AA . | Sequences producing the highest significant similarity . | E value4-150 . | VH family/gene . | DH segment . | JH segment . |
|---|---|---|---|---|---|---|---|
| 1 | CAREQDYDTSSYYYGYWGQGTLV | 13 | RF-WOL | 6e-05 | VHI/DP-88 | D21/9 | J4 |
| 2 | CARGTDSSNYYYFYWGQGTLV | 11 | RF-WOL | 0.002 | VHI/DP-88 | D21/9 | J2 |
| 3 | CARAFSSDTSGYYYYWGQGTLV | 12 | RF-WOL | 0.005 | VHI/DP-10 | D21/9 | J4 |
| 4 | CARGPETSGYYYFYWGQGTLV | 11 | RF-WOL | 0.005 | VHIII/DP-47 | D21/9 | J4 |
| 5 | CARGDYYDTSGYFSDAFDIWGQGTLV | 16 | RF-WA | 1e-06 | VHIII/DP-54 | D21/9 | J3 |
| 6 | CARGDYDNSGDFVDAFDIWGQGTLV | 15 | RF-WA | 1e-05 | VHIII/DP-54 | D21/10 | J3 |
| 7 | CARDRFCSGGSCFDWYFDLWGQGTLV | 19 | RF-MR-20/HCV | 2e-07/1e-04 | VHIV/DP-71 | D2 | J2 |
| 8 | CARDYGGSSGYLNWFDPWGQGTLV | 14 | RF | 4e-05 | VHIII/DP-51 | D21/9 | J5 |
| 9 | CARDLCSGGSCPALGAIDYWGEGTLV | 16 | RF-C93 | 0.017 | VHI/DP-75 | D2 | J4 |
| 10 | CARGDYFDDDGPFIDVFNVWGQGTLV | 17 | RF-WA | 9e-06 | VHIII/DP-54 | D5-24 | J3 |
| 11 | CARGAYYNFFGDSYHYLDYWGQGTLV | 16 | RF-WA | 0.030 | VHIII/DP-47 | DXP1 | J4 |
| 12 | CARDSFCTGGSCFDWYFDWGQG | 15 | RF-MR-20/HCV | 7e-06/0.023 | VHIV/DP-71 | D2 | J5/J2 |
| 13 | CTSTGDRALVYSYDFWGQGTLV | 19 | RF-BOR | 1700 | VHIV/DP-63 | D5-18/DK4 | J4 |
| 14 | CAQGGFSTSWYVPTGGYWGQGTLV | 21 | RF-10-2 | 1000 | VHIII/DP-49 | DN1 | J4 |
| 15 | CARAPTRMGPLWELGYYFDCWGQGTLV | 17 | RF/HCV | 0.030/0.15 | VHIII/DP-54 | DN4 | J4 |
| 16 | CERSKYFDSWSGECVSARESHFDYWGQGTLV | 21 | RF | 0.010 | VHI/DP-8 | DXP4 | J4 |
| 17 | CARANKEQWLVLEYNWFDPWGQGTLV | 16 | RF | 2e-04 | VHIII/DP-51 | D6-19 | J5 |
| Patient no. . | IgH CDR3 deduced amino acid sequences . | Length of CDR3 AA . | Sequences producing the highest significant similarity . | E value4-150 . | VH family/gene . | DH segment . | JH segment . |
|---|---|---|---|---|---|---|---|
| 1 | CAREQDYDTSSYYYGYWGQGTLV | 13 | RF-WOL | 6e-05 | VHI/DP-88 | D21/9 | J4 |
| 2 | CARGTDSSNYYYFYWGQGTLV | 11 | RF-WOL | 0.002 | VHI/DP-88 | D21/9 | J2 |
| 3 | CARAFSSDTSGYYYYWGQGTLV | 12 | RF-WOL | 0.005 | VHI/DP-10 | D21/9 | J4 |
| 4 | CARGPETSGYYYFYWGQGTLV | 11 | RF-WOL | 0.005 | VHIII/DP-47 | D21/9 | J4 |
| 5 | CARGDYYDTSGYFSDAFDIWGQGTLV | 16 | RF-WA | 1e-06 | VHIII/DP-54 | D21/9 | J3 |
| 6 | CARGDYDNSGDFVDAFDIWGQGTLV | 15 | RF-WA | 1e-05 | VHIII/DP-54 | D21/10 | J3 |
| 7 | CARDRFCSGGSCFDWYFDLWGQGTLV | 19 | RF-MR-20/HCV | 2e-07/1e-04 | VHIV/DP-71 | D2 | J2 |
| 8 | CARDYGGSSGYLNWFDPWGQGTLV | 14 | RF | 4e-05 | VHIII/DP-51 | D21/9 | J5 |
| 9 | CARDLCSGGSCPALGAIDYWGEGTLV | 16 | RF-C93 | 0.017 | VHI/DP-75 | D2 | J4 |
| 10 | CARGDYFDDDGPFIDVFNVWGQGTLV | 17 | RF-WA | 9e-06 | VHIII/DP-54 | D5-24 | J3 |
| 11 | CARGAYYNFFGDSYHYLDYWGQGTLV | 16 | RF-WA | 0.030 | VHIII/DP-47 | DXP1 | J4 |
| 12 | CARDSFCTGGSCFDWYFDWGQG | 15 | RF-MR-20/HCV | 7e-06/0.023 | VHIV/DP-71 | D2 | J5/J2 |
| 13 | CTSTGDRALVYSYDFWGQGTLV | 19 | RF-BOR | 1700 | VHIV/DP-63 | D5-18/DK4 | J4 |
| 14 | CAQGGFSTSWYVPTGGYWGQGTLV | 21 | RF-10-2 | 1000 | VHIII/DP-49 | DN1 | J4 |
| 15 | CARAPTRMGPLWELGYYFDCWGQGTLV | 17 | RF/HCV | 0.030/0.15 | VHIII/DP-54 | DN4 | J4 |
| 16 | CERSKYFDSWSGECVSARESHFDYWGQGTLV | 21 | RF | 0.010 | VHI/DP-8 | DXP4 | J4 |
| 17 | CARANKEQWLVLEYNWFDPWGQGTLV | 16 | RF | 2e-04 | VHIII/DP-51 | D6-19 | J5 |
Smallest sum probability according to the BLAST similarity search program. The E value is inversely related to statistical significance and is considered significant for a value below 0.05.
Genbank accession numbers for RF-WOL: prf0707281c; RF-WA: U03400; RF-MR-20: U85234; anti E2 protein of HCV: AJ236544 for patient 7 and 12 and AJ236543 for patient 15; RF: AF021950 for patient 8, AF021978 for patient 15, AF021967 for patient 16 and AF022007 for patient 17; RF-C93: 573143; RF-BOR: prf1313976A; RF-10-2: S74542.